Immunoregulation of GVHD by triggering the innate immune system with CpG (Q37810081)

https://api.crossref.org/works/10.1586/EHM.09.29

23 August 2017

title

Immunoregulation of GVHD by triggering the innate immune system with CpG (English)

1 reference

28 August 2024

author name string

Shoshana Morecki

1

1 reference

23 August 2017

Shimon Slavin

2

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21082948

28 August 2024

publication date

1 August 2009

1 reference

full work available at URL

23 August 2017

http://www.future-drugs.com/doi/abs/10.1586/ehm.09.29

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21082948

http://www.tandfonline.com/doi/pdf/10.1586/ehm.09.29

28 August 2024

1 reference

https://api.crossref.org/works/10.1586/EHM.09.29

Expert Review of Hematology

28 August 2024

published in

1 reference

23 August 2017

volume

2

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

443-453

1 reference

Toll-like receptor control of the adaptive immune responses

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Antiinfective applications of toll-like receptor 9 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Toll-like receptors in the respiratory system: their roles in inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

How I treat refractory acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Pathophysiology of acute graft-versus-host disease: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Prevention and treatment of acute GvHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Derangement of immune responses by myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Advances in the clinical management of GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Graft-versus-host disease: how to translate new insights into new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

In vitro experiments demonstrate that monocytes and dendritic cells are rendered apoptotic by extracorporeal photochemotherapy, but exhibit unaffected surviving and maturing capacity after 30 Gy gamma irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Shared biology of GVHD and GVT effects: potential methods of separation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Modulation of graft-versus-host disease: role of regulatory T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Suppression of graft-versus-host disease after adoptive infusion of alloreactive NK cells induced by silencing Ly49C gene in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Effect of KRN7000 on induced graft-vs-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

IL-17 contributes to CD4-mediated graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

The use of growth factors in hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Therapeutic benefits of regulating inflammation in autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEHM.09.29

TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity

21 January 2018

https://api.crossref.org/works/10.1586/EHM.09.29

5

1 reference

Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

7

1 reference

CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

8

1 reference

CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

14

1 reference

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

17

1 reference

Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

19

1 reference

Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

24

1 reference

TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-theta signaling and promote autoimmune myocarditis

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

26

1 reference

Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

31

1 reference

Protein kinase D1: a new component in TLR9 signaling

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

33

1 reference

Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

34

1 reference

TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

36

1 reference

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

41

1 reference

Protective conditioning for acute graft-versus-host disease

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

42

1 reference

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

52

1 reference

A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

55

1 reference

Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

56

1 reference

Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

57

1 reference

Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

59

1 reference

Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

64

1 reference

Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

66

1 reference

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

67

1 reference

NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

69

1 reference

Stimulation of Host NKT Cells by Synthetic Glycolipid Regulates Acute Graft-versus-Host Disease by Inducing Th2 Polarization of Donor T Cells

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

72

1 reference

Role of type II NKT cells in the suppression of graft-versus-host disease

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

73

1 reference

Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

78

1 reference

Therapeutic effect of CpG motifs on the development of chronic graft-versus-host disease in mice

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

90

1 reference

Regulation of Autoimmune Diabetes by Complete Freund's Adjuvant Is Mediated by NK Cells

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

92

1 reference

Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators

28 August 2024

https://api.crossref.org/works/10.1586/EHM.09.29

94

1 reference

28 August 2024

Identifiers

DOI

10.1586/EHM.09.29

1 reference

release_gfcdlrdtdbadzjbkiuquvenxoe

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gfcdlrdtdbadzjbkiuquvenxoe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference